Last Update Time:
17-Mar-2025 16:00:00
ISIN:
INE767A01016
Sector:
Healthcare
Symbol:
AARTIDRUGS
Aarti Drugs Limited
₹332.75
₹-7.45
(-2.19%)
▼
Prev. Close
₹340.20
Open
₹339.05
Close
₹333.20
Range
₹316.11 - ₹349.39
High
₹342.05
Low
₹330.05
Ind. Close
₹0.00
VWAP
₹336.18
The current stock price of Aarti Drugs Limited is ₹332.75, with a target price range between ₹316.11 and ₹349.39. The stock has experienced a price change of ₹-7.45 (-2.19%), reflecting recent market volatility.
Today's opening price was ₹339.05, while the previous close stood at ₹340.20.
The market trend suggests a potential downtrend, with investors exercising caution due to recent declines. Analysts recommend closely monitoring support levels.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Aarti Drugs Limited Price Chart
Aarti Drugs Limited Pre Open Market Overview: 17-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 339.05
- Previous Close Price: 340.2
- Change: -1.15%
- Total Traded Volume: 637
- Total Buy Quantity: 5,485
- Total Sell Quantity: 10,818
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 336.00 | 65.00 | 0.00 |
| 336.60 | 20.00 | 0.00 |
| 336.70 | 5.00 | 0.00 |
| 337.10 | 3.00 | 0.00 |
| 338.75 | 78.00 | 0.00 |
| 339.00 | 0.00 | 22.00 |
| 339.05 | 0.00 | 45.00 |
| 339.70 | 0.00 | 203.00 |
| 339.90 | 0.00 | 3.00 |
| 339.95 | 0.00 | 105.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 5485
Total Sell Quantity: 10818
Shareholding Patterns of Aarti Drugs Limited
Key Trade Statistics of Aarti Drugs Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 1.45 |
| Traded Value (₹ Cr.) | 4.87 |
| Total Market Cap (₹ Cr.) | 3,037.01 |
| Free Float Market Cap (₹ Cr.) | 1,148.93 |
| Impact cost | 0.09 |
| Quantity Traded | 144,760.00 |
| Deliverable Quantity | 74,750.00 |
| % of Quantity to Traded | 51.64 |
| Security VaR | 13.75 |
| Index VaR | N/A |
| VaR Margin | 13.75 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 17.25 |
| Face Value | 10 |
Key Price Statistics of Aarti Drugs Limited
The 52-week high for Aarti Drugs Limited was ₹635.00, recorded on 27-Aug-2024. On the other hand, the 52-week low stands at ₹330.05, with the lowest value recorded on 17-Mar-2025.
The upper band for trading is ₹408.20, and the lower band is ₹272.20. The price band is 20%.
The stock's daily volatility stands at 2.15, while the annualized volatility is 41.08. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (27-Aug-2024) | 635.00 |
| 52 Week Low (17-Mar-2025) | 330.05 |
| Upper Band | 408.20 |
| Lower Band | 272.20 |
| Price Band (%) | 20 |
| Daily Volatility | 2.15 |
| Annualised Volatility | 41.08 |
| Tick Size | 0.05 |
Key Securities Statistics of Aarti Drugs Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 19-Sep-2003 |
| Adjusted P/E | 20.34 |
| Symbol P/E | 20.34 |
| Index | NIFTY TOTAL MARKET |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Aarti Drugs Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Aarti Drugs Limited
| Subject | Date |
|---|---|
| Analysts/Institutional Investor Meet/Con. Call Updates | 17-Mar-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 11-Mar-2025 |
| Action(s) taken or orders passed | 07-Mar-2025 |
| Action(s) taken or orders passed | 06-Mar-2025 |
| General Updates | 03-Mar-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 28-Feb-2025 |
| Action(s) taken or orders passed | 14-Feb-2025 |
| Action(s) taken or orders passed | 07-Feb-2025 |
Corporate Actions of Aarti Drugs Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 10 | Interim Dividend - Re 1 Per Share | 04-Feb-2025 |
| 10 | Buy Back | 05-Sep-2024 |
| 10 | Interim Dividend - Re 1 Per Share | 06-Feb-2024 |
| 10 | Buy Back | 04-Aug-2023 |
| 10 | Interim Dividend - Rs 1 Per Share | 08-Feb-2023 |
| 10 | Interim Dividend - Re 1 Per Share | 09-Feb-2022 |
| 10 | Buyback | 30-Mar-2021 |
| 10 | Interim Dividend - Rs 2.5 Per Share | 03-Nov-2020 |
| 10 | Bonus 3:1 | 30-Sep-2020 |
| 10 | Interim Dividend - Rs 2 Per Share | 17-Feb-2020 |
| 10 | Annual General Meeting/Dividend - Re 1 Per Share | 26-Jul-2019 |
| 10 | Buyback | 28-Mar-2019 |
| 10 | Annual General Meeting/Dividend- Re 1 Per Share | 01-Aug-2018 |
| 10 | Buyback | 18-Jan-2018 |
| 10 | Annual General Meeting/Dividend - Re 1/- Per Share | 09-Aug-2017 |
| 10 | Buy Back | 01-Nov-2016 |
| 10 | Annual General Meeting | 13-Jul-2016 |
| 10 | Interim Dividend - Rs 3/- Per Share (Purpose Revised) | 22-Mar-2016 |
| 10 | Interim Dividend - Rs 1.50/- Per Share (Purpose Revised) | 12-Feb-2016 |
| 10 | Interim Dividend - Rs 2.25/- Per Share (Purpose Revised) | 10-Nov-2015 |
Board Meetings of Aarti Drugs Limited
Financial Results of Aarti Drugs Limited
Company Directory of Aarti Drugs Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| N/A | Head Office/ Corporate Office | Ground Floor Mahendra Industrial Estate, Plot No. 109-D,Road No.29, Sion (East) | MUMBAI |
| N/A | Registered Office | Plot No. N-198 MIDC, Tarapur Village Pamtembhi, Tal. Palghar | PALGHAR |
| N/A | Transfer Agent | Link Intime India Private Limited C 101, 247 Park, L.B.S. Marg, Vikhroli (West), | MUMBAI |
Insider Trading of Aarti Drugs Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Harshit Manilal Savla | 6170924 | Buy |
| 7(2) | Prakash Moreshwar Patil | 22036651 | Buy |
| 7(2) | Seema Harshit Savla | 4848582 | Buy |
| 7(2) | Renil Rajendra Gogri | 72072454 | Sell |
| 7(2) | Harit Pragji Shah | 11019474 | Buy |
| 7(2) | Alchemie Finserv Pvt. Ltd. | 23390780 | Buy |
| 7(2) | Rashesh Chandrakant Gogri | 52864339 | Buy |
| 7(2) | Renil Rajendra Gogri | 79340927 | Sell |
| 7(2) | Alchemie Finserv Pvt. Ltd. | 30726201 | Buy |
| 7(2) | Arun Moreshwar Patil | 279746 | Buy |
| 7(2) | Uday Moreshwar Patil | 258853 | Buy |
| 7(2) | Uday Moreshwar Patil | 229854 | Buy |
| 7(2) | Uday Moreshwar Patil | 10412 | Buy |
| 7(2) | Uday Moreshwar Patil | 260491 | Buy |
| 7(2) | Prakash Moreshwar Patil | 4326484 | Buy |
| 7(2) | Safechem Enterprises Private Limited | 5240626 | Sell |
| 7(2) | Safechem Enterprises Private Limited | 37377939 | Sell |
| 7(2) | Safechem Enterprises Private Limited | 6906825 | Sell |
| 7(2) | Safechem Enterprises Private Limited | 1002422 | Sell |
| 7(2) | Safechem Enterprises Private Limited | 23540777 | Sell |
Annual Reports of Aarti Drugs Limited
Investor Complaints of Aarti Drugs Limited
Event Calendar of Aarti Drugs Limited
| Purpose | Details |
|---|---|
| Results/Dividend | Interalia, to consider, approve and take on record the audited financial results and accounts for the quarter & year ended March 31, 2010 and to consider recommendation of dividend, if any. |
| Results/Dividend | Inter-alia to: 1) consider, approve and take on record the audited financial results and accounts for the quarter ended December 31, 2010. 2) Consider declaration of Interim Dividend, if any. |
| Results/Dividend | Inter-alia to: 1) consider, approve and take on record the audited financial results and accounts for the quarter and year ended on March 31, 2011. 2) Consider declaration of final Dividend, if any. |
| Results/Dividend | inter -alia to: (1) Consider , approve and to take on record audited financial results and accounts for the quarter and nine months ended December 31, 2011. (2) Consider declaration of interim Dividend , if any. |
| Results/Dividend | Inter-alia to: 1) consider, approve and take on record the audited financial results and accounts for the quarter and year ended on March 31, 2012. 2) Consider declaration of final Dividend, if any. |
| Results/Others | Inter-alia to: (1) Reconsider, approve and take on record the Audited Financial Results for the year ended March 31, 2012, post amalgamation of Suyash Laboratories Limited (Wholly-owned subsidiary of the Company) with the Company approved by the Bombay High Court on May 11, 2012, to be effective from April 01, 2011. |
| Results/Dividend | Inter-alia to : (1) Consider, approve and take on record audited financial results and accounts for the quarter and half year ended on September 30, 2012; (2) Consider declaration of Interim Dividend, if any. |
| Results/Dividend | Inter -alia to: (1) Consider, approve and to take on record audited financial results and accounts for the quarter and nine months ended December 31, 2012. (2) Consider declaration of 2nd Interim Dividend, if any. |
| Results/Dividend | Inter -alia to: (1) Consider, approve and take on record audited financial results and accounts for the quarter and year ended on 31st March, 2013. (2) Consider declaration of final dividend, if any. |
| Results/Others | To consider, approve and take on record the Audited Financial Results and Accounts for the quarter ended 30th June, 2013. |
| Results/Dividend | Inter-alia to : (1) Consider, approve and take on record audited financial results and accounts for the quarter and half year ended on September 30, 2013; (2) Consider declaration of Interim Dividend, if any. |
| Results/Dividend | 1. Consider, approve and take on record audited financial results and accounts for the quarter ended on 31st December, 2013. 2.Consider declaration of 2nd Interim Dividend, if any. |
| Results/Dividend | Inter -alia to: 1. Consider, approve and take on record audited financial results and accounts for the quarter and year ended on March 31, 2014. 2. Consider declaration of final dividend, if any. |
| Results | Inter-alia, to consider, approve and take on record the audited financial results and accounts for the quarter ended June 30, 2014. |
| Results/Dividend | Inter-alia to: 1. Consider, approve and take on record audited financial results and accounts for the quarter and half year ended on September 30, 2014. 2. Consider declaration of Interim dividend, if any. |
| Results/Dividend | Inter-alia to : (1) Consider, approve and take on record audited financial results and accounts for the quarter and nine month ended on December 31, 2014. (2) Consider declaration of 2nd Interim Dividend, if any. |
| Results/Dividend | Inter-alia to; 1. Consider, approve and take on record audited financial results and accounts for the quarter and year ended on March 31, 2015. 2. Consider recommendation of final dividend, if any. |
| Results | inter alia to consider, approve and take on record audited financial results and accounts for the quarter ended June 30, 2015. |
| Results/Dividend | inter alia to:1. Consider, approve and take on record audited financial results and accounts for the quarter and half year ended on September 30, 2015.2. Consider declaration of Interim dividend, if any. |
| Results/Dividend | Inter-alia to : (1) Consider, approve and take on record Audited Financial Results and Accounts for the quarter and nine month ended on December 31, 2015. (2) Consider declaration of 2nd Interim Dividend, if any. |
| Dividend | Inter-alia, to consider declaration of 3rd Interim Dividend for the financial year 2015-16, if any. |
| Results | inter-alia, to consider, approve and take on record Audited Financial Results and Accounts for the quarter and year ended on March 31, 2016. |
| Results | Inter-alia, to consider, approve and take on record Audited Financial Results and Accounts for the quarter ended June 30, 2016. |
| Buyback | to consider, inter-alia, proposal of buyback of the fully paid-up equity shares of the Company including matters related / incidental thereto. |
| Results | inter-alia, to consider, approve and take on record Audited Financial Results and Accounts for the quarter and half year ended September 30, 2016. |
| Results | inter-alia, to consider, approve and take on record Audited Financial Results and Accounts for the quarter and nine months ended December 31, 2016. Further, that in accordance with Code of Conduct for Prevention of Insider Trading framed by the Company pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the securities of the Company will be closed for all Designated Persons (as defined in the code) of the Company from February 01, 2017 to February 10, 2017 (both days inclusive). |
| Results | inter-alia, to consider, approve and take on record Audited Financial Results and Audited Financial Statements (Standalone and Consolidated) for the quarter and year ended on March 31, 2017. |
| Board meeting Rescheduled | The Company had informed the Exchange regarding a meeting of the Board of Directors of the Company schedule to be held May 18, 2017, inter-alia, to consider, approve and take on record Audited Financial Results and Audited Financial Statements (Standalone and Consolidated) for the quarter and year ended on March 31, 2017. The Company has now informed the Exchange that the meeting of the Board of Directors has now been postponed to May 23, 2017 (Revised). |
| Results/Dividend | AARTIDRUGS : 23-May-2017 : The Company had informed the Exchange regarding a meeting of the Board of Directors of the Company schedule to be held May 18, 2017, inter-alia, to consider, approve and take on record Audited Financial Results and Audited Financial Statements (Standalone and Consolidated) for the quarter and year ended on March 31, 2017. The Company has now informed the Exchange that the meeting of the Board of Directors has now been postponed to May 23, 2017, and will consider and recommend final dividend, if any. (Purpose Revised) |
| Results | Inter-alia, to consider, approve and take on record Audited Financial Results for the quarter ended June 30, 2017. |
| Results | inter-alia, to consider, approve and take on record Audited Financial Results and Accounts for the quarter and half year ended 30th September, 2017 |
| Buyback | To consider inter alia, proposal of buyback of the fully paid-up equity shares of the Company including matters related/incidental thereto. |
| Results | Inter-alia, to consider, approve and take on record Audited Financial Results and Accounts for the quarter and nine months ended December 31, 2017. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2018 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Buyback | To consider buyback for equity shares. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2019 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2019 and dividend |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2020 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Bonus | This is to inform you that next Board Meeting of the Board of Directors of the Company is scheduled to be held on Thursday, August 20, 2020 to consider a proposal for issue of Bonus Shares.In pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, read with Company s Code on prohibition of Insider Trading, the Company is closing the Trading Window with immediate effect and it will remain closed until August 22, 2020 for the aforesaid purpose. |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Dividend/Fund Raising | To consider dividend and Fund Raising |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Buyback | To consider buyback for equity shares |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2021 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2021 and dividend |
| Financial results | Aarti Drugs Limited has informed the Exchange about Board Meeting to be held on 09-May-2022 to consider financial statements for the period ended March 2022 |
| Financial results | Aarti Drugs Limited has informed the Exchange about Board Meeting to be held on 27-Jul-2022 to consider financial statements for the period ended June 2022 |
| Financial results | Aarti Drugs Limited has informed the Exchange about Board Meeting to be held on 20-Oct-2022 to consider financial statements for the period ended September 2022 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2022 and dividend |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2023 |
| Financial Results/Buyback | To consider and approve the financial results for the period ended Jun 30, 2023 and buyback for equity shares |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2023 and Interim dividend for the FY 2023-24, if any |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2024 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Buyback | To consider buyback for equity shares |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2024 and dividend |
Share Transfers of Aarti Drugs Limited
Voting Results of Aarti Drugs Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 20-SEP-2024 | AGM | To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31, 2024, together with the Reports of the Board of Directorsￂ and the Auditors thereon. |
| 20-SEP-2024 | AGM | Ratification of remuneration of Cost Auditors for FY 2024-25 |
| 20-SEP-2024 | AGM | Revision in the terms & conditions of appointment of Shri Uday Moreshwar Patil (DIN: 01186406), Executive Director of the Company |
| 20-SEP-2024 | AGM | Re-appointment of Smt. Neha Rajen Gada (DIN: 01642373) as an Independent Director |
| 20-SEP-2024 | AGM | Re-appointment of Shri Bhaskar Narayan Thorat (DIN: 01293824) as an Independent Direct |
| 20-SEP-2024 | AGM | Re-appointment of Shri Ankit Vikram Paleja (DIN: 06975564) as an Independent Director |
| 20-SEP-2024 | AGM | To appoint a Director in place of Shri Narendra Jagannath Salvi (DIN: 00299202), who is liable to retire by rotation and being eligible, offers himself for re-appointment |
| 15-JUN-2024 | Postal Ballot | Approval to the appointment of Shri Hasmukh Bhavanji Dedhia (DIN: 07510925) as an Independent Director of the Company. |
| 15-JUN-2024 | Postal Ballot | Approval to the appointment of Shri Sandeep Madhusudan Joshi (DIN: 00516409) as an Independent Director of the Company. |
| 15-JUN-2024 | Postal Ballot | Approval to the appointment of Shri Ajit Eledath Venugopalan (DIN: 09439069) as an Independent Director of the Company. |
| 26-SEP-2023 | AGM | Adoption of Financial Statement (Standalone & Consolidated) for the Financial Year ended March 31, 2023, together with the Reports of the Directors and Auditors thereon. |
| 26-SEP-2023 | AGM | Ratification of remuneration to be paid to the Cost Auditors for FY 2023-24 |
| 26-SEP-2023 | AGM | Approval to Smt Richie Gandhi to continue to hold office or place of profit with revised Remuneration. |
| 26-SEP-2023 | AGM | Appointment of Gokhale & Sathe, Chartered Accountants as Statutory Auditors of the Company |
| 26-SEP-2023 | AGM | Re-appointment of Shri Harit P.Shah (DIN: 00005501), who retires by rotation and being eligible, seeks re-appointment. |
| 29-OCT-2022 | Postal Ballot | Ordinary Resoution for re-apppointment of Shri Rashesh C. Gogri (DIN:00066291) as the Managing Director of the Company. |
| 04-AUG-2022 | AGM | Adoption of Financial Statement (Standalone & Consolidated) for the Financial Year ended March 31, 2022 together with the Reports of the Directors and Auditors thereon |
| 04-AUG-2022 | AGM | Approval to the Appointment of Smt Neha R. Gada (DIN:01642373) As an Independent Director of the Company |
| 04-AUG-2022 | AGM | Approval to the Appointment of Shri Bhaskar N. Thorat (DIN:01293824) As an Independent Director of the Compnay. |
| 04-AUG-2022 | AGM | Re-appointment of Shri Uday M. Patil (DIN: 01186406), who retires by rotation and being eligible, seeks re-appointment. |
FAQs on Aarti Drugs Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.